Table 5. Mutations (including Missense point mutations/deletion/insertion) frequencies in 45 genes (737 loci) in metastasis and non-metastasis lung cancer patients.
| Genes | Number of samples with mutations (Mutation frequency in 76 samples) | Number of non-metastasis samples with mutations (Mutation frequency in 16 samples) | Number of local metastasis samples with mutations (Mutation frequency in 8 samples) | Number of lymph metastasis samples with mutations (Mutation frequency in 11 samples) | Number of far metastasis samples with mutations (Mutation frequency in 39 samples) | Number of unknown samples with mutations (Mutation frequency in 2 samples) |
| ABL1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| AKT1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| ALK | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| APC | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| ATM | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| BRAF | 2(2.6%) | 0(0.0%) | 0(0.0%) | 1(9.1%) | 1(2.6%) | 0(0.0%) |
| CDH1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| CDKN2A | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| CSF1R | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| CTNNB1 | 3(3.9%) | 0(0.0%) | 1(12.5%) | 0(0.0%) | 2(5.1%) | 0(0.0%) |
| EGFR | 32(42.1%) | 7(43.8%) | 4(50.0%) | 3(27.3%) | 18(46.2%) | 0(0.0%) |
| ERBB2 | 1(1.3%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(2.6%) | 0(0.0%) |
| ERBB4 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| FBXW7 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| FGFR1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| FGFR2 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| FGFR3 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| FLT3 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| GNAS | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| HNF1A | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| HRAS | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| IDH1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| JAK3 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| KDR | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| KIT | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| KRAS | 4(5.3%) | 1(6.3%) | 0(0.0%) | 1(9.1%) | 2(5.1%) | 0(0.0%) |
| MET | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| MLH1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| MPL | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| NOTCH1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| NPM1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| NRAS | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| PDGFRA | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| PIK3CA | 2(2.6%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 2(5.1%) | 0(0.0%) |
| PTEN | 1(1.3%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(2.6%) | 0(0.0%) |
| PTPN11 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| RB1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| RET | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| SMAD4 | 1(1.3%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(2.6%) | 0(0.0%) |
| SMARCB1 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| SMO | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| SRC | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| STK11 | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| TP53 | 17(22.4%) | 2(12.5%) | 2(25.0%) | 6(54.5%) | 5(12.8%) | 2(100.0%) |
| VHL | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |